Intranasal Nanodelivery of Oxytocin to Treat Morphine Addiction in HIV Patients by Gene Editing

通过基因编辑鼻内纳米递送催产素治疗 HIV 患者吗啡成瘾

基本信息

  • 批准号:
    9411292
  • 负责人:
  • 金额:
    $ 14.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-07-01 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

Intranasal Nanodelivery of Oxytocin to Treat Morphine Addiction in HIV Patients by Gene Editing Despite significant developments, treating drug addiction in HIV-1 infected subjects remain as a challenge. Morphine has been shown to exaggerate HIV-induced risk in patients, which deteriorates the brain function and leads to dysregulation of endocrine-metabolic system. This dysregulation might lead to disturbances in the hypothalamic-pituitary-thyroid (HPT) axis, which may indirectly effect the production of Oxytocin (OXT) (neurohypophyseal nona-neuropeptide synthesized in the brain released at the posterior pituitary). Despite the extensive literature on OXT's role in addiction therapy, there are no direct studies available investigating the effects of or on OXT during concurrent Morphine addiction and HIV-1 infection. Also, it has previously been shown that exogenous OXT delivery inhibits the development of acute and chronic morphine tolerance and attenuate the various symptoms of morphine withdrawal in dose dependent manner. OXT may act as a neuromodulator on dopaminergic neurotransmission in limbic-basal forebrain structures to regulate adaptive CNS processes leading to drug addiction. Repeated morphine ingestion will upregulate mu (µ)-opioid receptor and lead to inhibition of OXT production, which may eventually cause the development of tolerance and physical dependence. Though the OXT has significant therapeutic advantages there are insufficient levels of OXT in compromised diseased state and exogenous OXT expressing source becomes an important need. Exogenous OXT delivery becomes complicated pertaining to factors like plasma half-life and poor oral bioavailability, and limited penetrance of the blood-brain barrier (BBB) due to their large size and hydrophilic nature. Therefore, delivery of a stable and efficacious active gene encoding protein directly into the brain that would reverse the effects of morphine addiction may serve as an effective approach against HIV-1 infected drug abusing subjects. Considering these preclinical limitations related to its delivery and to address this issue, we have developed a novel polyplex nanoformulation of OXT encoding CRISPR activation plasmid by lab developed nontoxic derivative of PEI [P(SiDAAr)5P3] using novel simultaneous spray (SS) technique. Our preliminary results show that SS prepared pGFP polyplex using P(SiDAAr)5P3 (non-viral transfecting agent) could form uniform, small, stable, non-toxic polyplex and achieved significant higher transfection efficiency compared to commercially available jetPEI. To translate this novel technology as anti-addiction therapeutics in HIV-1 treatment paradigm and to achieve the goals, we propose to study the effect of spraying parameters, important formulation aspects and efficacy evaluation of SS-prepared OXT- formulation against Morphine ± HIV-1 Tat challenge using primary human neurons (Aim-1). generate i nhalable aerosol formulation of OXT- P(SiDAAr)5P3 polyplex Further as a proof of concept, we propose to P(SiDAAr)5P3 polyplex and evaluate intranasal CNS delivery in OXTtm1Wsy/OXTtm1Wsy (OXT deficient- OXTDef) mice exposed to Morphine ± HIV-1 Tat (Aim-2). Data generated using this grant will be used for future R01 grant proposal.
鼻内纳米递送催产素通过基因编辑治疗HIV患者的吗啡成瘾 尽管取得了重大进展,但治疗HIV-1感染受试者的药物成瘾仍然是一个挑战。 吗啡已被证明会夸大患者中艾滋病毒诱导的风险,从而使大脑功能恶化 并导致内分泌代谢系统失调。这种失调可能会导致 下丘脑-垂体-甲状腺(HPT)轴,可能间接影响催产素(OXT)的产生 (神经垂体九肽-脑内合成的神经肽,在垂体后叶释放)。尽管 关于OXT在成瘾治疗中的作用的大量文献中,没有直接的研究可以调查 吗啡成瘾和HIV-1感染同时发生时OXT的影响。此外,此前 已经显示外源性OXT递送抑制急性和慢性吗啡耐受性的发展 并以剂量依赖性方式减轻吗啡戒断的各种症状。 OXT可以作为 边缘-基底前脑结构多巴胺能神经传递调节适应性 导致药物成瘾的CNS过程。 重复摄入吗啡将上调μ-阿片类药物 受体,并导致抑制OXT的生产,这可能最终导致耐受性的发展 身体依赖。尽管OXT具有显著的治疗优势,但仍存在不足。 受损疾病状态中的OXT水平和外源性OXT表达源成为重要的 需要的外源性OXT递送变得复杂,涉及血浆半衰期和口服不良等因素。 由于它们的大尺寸和亲水性, 自然因此,将编码蛋白质的稳定和有效的活性基因直接递送到脑中, 将逆转吗啡成瘾的影响可能成为对抗HIV-1感染的有效方法 药物滥用主题。考虑到这些与其输送相关的临床前限制, 问题,我们已经开发了编码CRISPR活化质粒的OXT的新型多聚复合物纳米制剂, 实验室使用新型同时喷雾(SS)技术开发了PEI [P(SiDAAr)5P3]的无毒衍生物。我们 初步结果表明,SS使用P(SiDAAr)5P3(非病毒分离剂)制备pGFP多聚物, 能形成均匀、细小、稳定、无毒的复合物,转染效率显著提高 与市售的jetPEI相比。将这种新技术转化为抗成瘾疗法 在HIV-1治疗范例中,为了实现目标,我们建议 研究了喷雾参数对喷雾效果的影响, SS制备的OXT的重要制剂方面和功效评价- 使用原代人神经元(Aim-1),对吗啡± HIV-1达特攻击的制剂进行了研究。 产生OXT的可吸入气雾剂制剂, P(SiDAAr)5P3 polyplex 进一步证明 提出了P(SiDAAr)5P3的概念 polyplex 和 评价暴露于吗啡的OXTtm1Wsy/OXTtm1Wsy(OXT缺陷-OXTDef)小鼠中的鼻内CNS递送 ± HIV-1达特(Aim-2)。使用此补助金生成的数据将用于未来的R01补助金提案。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Rahul Dev Jayant其他文献

Rahul Dev Jayant的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Rahul Dev Jayant', 18)}}的其他基金

Intranasal Nanodelivery of Oxytocin to Treat Morphine Addiction in HIV Patients by Gene Editing
通过基因编辑鼻内纳米递送催产素治疗 HIV 患者吗啡成瘾
  • 批准号:
    9823923
  • 财政年份:
    2017
  • 资助金额:
    $ 14.65万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 14.65万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了